Abcam, ab261743, Human FANCD2 knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
FANCD2 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon 13. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 4 bp deletion in exon 13,
Antibiotic resistance:Puromycin 1µg/mL,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-FANCD2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FANCD2 also known as Fanconi anemia group D2 functions mechanically in DNA repair processes. This protein plays a role in the cellular response to DNA damage specifically interstrand crosslinks. FANCD2 has a molecular weight of approximately 164 kDa. Expression of FANCD2 occurs broadly in various tissues but reaches higher levels in cells that undergo rapid division such as hematopoietic cells.
Biological function summary
FANCD2 collaborates with multiple proteins as part of the Fanconi anemia (FA) complex to ensure genomic stability. The FA complex operates by facilitating the repair of DNA interstrand crosslinks that impede replication. FANCD2 becomes activated through monoubiquitination which serves as a signal for recruitment to DNA damage sites. It essentially functions as a coordinator that brings together important components for repair.
Pathways
FANCD2 integrates into the Fanconi anemia pathway and the homologous recombination repair pathway. These pathways are critical for maintaining DNA integrity and preventing chromosomal instability. Within these pathways interactions with proteins such as BRCA1 and BRCA2 reinforce the repair processes. FANCD2's connection to these proteins exemplifies its role in complex mechanisms that preserve genomic fidelity.
FANCD2 links significantly to Fanconi anemia a genetic disorder that causes bone marrow failure and increased cancer susceptibility. Damage or malfunction of FANCD2 can disrupt DNA repair leading to cellular dysfunction seen in this condition. Additionally there is a connection to breast cancer whereby FANCD2 interacts with BRCA2 indicating a shared pathway involved in tumor suppressor functions. These associations underline the importance of FANCD2 in disease pathology and its potential as a therapeutic target.